Trial Profile
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Anal cancer; Appendiceal cancer; Biliary cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Gynaecological cancer; Intestinal cancer; Lung cancer; Mesothelioma; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Salivary gland cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Vulvovaginal cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-158
- Sponsors Merck Sharp & Dohme Corp.
- 24 Oct 2023 Results (database cut off Jul 26,2022, n=24) in cohort L of KEYNOTE-158 assessing efficacy and safety of pembrolizumab in pts of Chinese descent with MSI-H/dMMR solid tumors presented at the 48th European Society for Medical Oncology Congress
- 29 Mar 2023 Pooled data from KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 studies presented in a Merck & Co media release.
- 29 Mar 2023 According to a Merck & Co media release, this conversion from accelerated to a full (regular) approval marks the first full approval for an immunotherapy based on a predictive biomarker, regardless of solid tumor type.